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Guillain-Barre syndrome (GBS) is a complicated degenerative neurological disorder which 
can be acute or chronic in nature. It is an acquired condition which is characterized by 
progressive, symmetrical, proximal and distal tingling and weakness. Muscle stretch reflexes 
are decreased to absent and loss of sensation is common. Etiology remains unclear but 
pathophysiology includes demyelination of spinal nerve roots. Death is rare. Early diagnosis 
and prompt referral should occur in severe cases due to the incidence of potential ventilation   
failure and cardiovascular instability in some patients. The case of a 26-year-old male 
presenting to a physician is described. The importance of a correct diagnosis by the physician 
and the subsequent management is reviewed.  
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Guillain-Barre Syndrome is a rare 
but serious autoimmune disease of the 
peripheral nervous system. GBS can affect 
people of any age or either sex, although it 
is slightly more common in older people 
and males. The condition usually begins 
following an infectious disease. The 
condition affects around 1 in 100,000 
people in the United States (U.S.). In the 
case of GBS, the immune system attacks 
the myelin sheaths of peripheral nerves. 
As the myelin is damaged, nerves can no 
longer send certain information to the 
spinal cord and brain, such as touch 
sensations1. This causes the sensation of 
numbness. In addition, the brain and spinal 
cord are no longer able to transmit signals 
back to the body, leading to muscle 
weakness1. The disease often begins with 
tingling sensations and weakness in the 
feet and legs. It then slowly spreads 
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upward until a large portion of the body is 
affected. The nerves connected to the 
lower extremities are the longest in the 
body. This travel distance makes these 
nerves more prone to a break in nerve 
signals due to GBS and its symptoms. 
Early diagnosis and prompt referral should 
occur in severe cases due to the incidence 
of potential ventilatory failure and 
cardiovascular instability in some patients. 
Nerve conduction exam, like 
Electromyography (EMG), lumbar 
puncture are the test used to diagnose the 
syndrome. Immunoglobulin therapy, 
plasma pheresis are the treatment options. 
The most common cause of acute muscle 
weakness associated with peripheral 
neuropathy in adults is Guillain-Barre 
syndrome.2 
This paper will discuss the causes, 
history, incidence and pathology of 
Guillain-Barre syndrome. The case of 37-
year old male is also presented. 
 
CASE REPORT 
A 26 old male admitted in hospital 
with complaints of pedal edema, facial 
puffiness, shortness of breath (10 days), 
abdominal distension positive, fever, 
nausea, body pains. His symptoms began 
slowly following an upper respiratory tract 
infection that he had about 14 days prior. 
No history of trauma, diabetic mellitus, 
and hypertension was reported. And it’s a 
known case of seizures on Eptoin 100mg. 
Examination of this man revealed 
healthy person and looks in good 
condition. Generalized weakness of the 
lower extremities was noted when testing 
the quadriceps, hamstrings and the 
gastrocnemius-soleus muscle groups. A 
general physical examination gave no 
other orthopedic, neurological, or organic 
findings. Respiratory and cardiac 
functions shown shortness of breath and 
cardiomegaly simultaneously. The patient 
was referred to his physician for lab work. 
Blood tests were ordered and the findings 
included an increase in the white blood cell 
count. The conclusion drawn from this 
was that this patient had recently suffered 
from some type of infection which 
correlated well with his history of an upper 
respiratory tract infection.  
Chest- X-ray shown cardiomegaly, 
creatinine phosphokinase test was normal. 
The patient was referred to his physician 
for lab work. Blood tests were ordered and 
the findings included an increase in the 
white blood cell count. The conclusion 
drawn from this was that this patient had 
recently suffered from some type of 
infection which correlated well with his 
history of an upper respiratory tract 
infection. Ultrasound of abdomen shown 
mild right pleural effusion, subcutaneous 
edema in bilateral legs more at the ankles 
noted. No evidence of dvt. 
A diagnosis of Guillain-Barre 
syndrome was made after utilizing the 
criteria that strongly support the diagnosis 
of Guillain Barre Syndrome. Features 
required to rule out diagnoses other than 
Guillain Barre Syndrome would include: 
no history of hexacarbon abuse, no 
evidence of porphyria, no history or 
culture evidence of diptheria, no history or 
evidence of lead intoxication, symptoms 
not purely sensory, no evidence of 
poliomyelitis, botulism, toxic neuropathy, 
or tick paralysis2. Therapeutic 
management of this included rest, 
nutritional support, patient education and 
periodic assessment of motor, respiratory, 
and cardiac function. Chiropractic care, 
which included spinal manipulative 
therapy to areas of subjective complaint, 
was palliative. Medical management was 
done with dobutamine infusion to treat 
cardiac failure as his report shown 
cardiomegaly. Diuretic has given to treat 
edema. Antibiotics have given to treat 
infections. This patient slowly improved 
so that he could return to work. 
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DISCUSSION 
Guillain-Barre syndrome (GBS) is 
also known as poly radiculoneuritis, and 
chronic inflammatory demyelinating poly 
radiculopathy (CIDP) 3. In North America 
it has an incidence of 1-7 per 100,000 
persons and as such is classified as one of 
the more common neurological 
conditions. It is the most common cause of 
acute weakness in patients under 40 years 
of age4.Diagnosis is difficult due to the 
lack of any test that is pathogenomonic of 
this condition. It is complicated disorder 
which can be chronic or acute in nature. 
It's etiology is unclear although it has been 
associated with both cell and humoral 
mediated autoimmune mechanisms5. 
Guillain-Barre syndrome represents an 
important acquired condition that is 
acutely evolving, is immune mediated, and 
an inflammatory disorder of the peripheral 
nervous system. It progresses leading to 
demyelination and axonal loss. Clinical 
hallmarks are symmetrical flaccid muscle 
paresis and areflexia in the presence of 
increased cerebrospinal fluid protein 
content and electro physiologic studies 
demonstrating evolving demyelination6. 
Causes such as viral infection7, surgery8, 9, 
10, blood transfusion11, and myco plasma 
infection12, vitamin B12 deficiency have 
been implicated as prodrome to this 
syndrome in many cases. The diagnosis of 
Guillain-Barre syndrome can be supported 
by the following clinical features as listed. 
 
Clinical features that strongly support 
the diagnosis of Guillain-Barre 
syndrome 
 
Upper respiratory tract infection 
Progression over days to weeks 
Mild sensory signs or symptoms 
Onset of recovery after 2 to 4 weeks of 
progression 
Elevated cerebrospinal fluid protein after 1 
week of symptoms 
Abnormal results of electro diagnostic 
studies, with slowed conduction or 
prolonged F waves 
Autonomic dysfunction 
Most patients develop weakness 
which tends to begin in the lower 
extremities due to demyelination of the 
peripheral nerves resulting in ascending 
paralysis and also loss of cranial nerve 
function12. Manifestations may be acute or 
chronic, and temporary or permanent, 
depending upon the degree of neuronal 
destruction13. Muscle stretch reflexes are 
depressed in most patients and the sensory 
loss is variable. Difficulty with walking, 
running, climbing stairs, and getting up 
from chair are usual early complaints. This 
weakness is usually symmetric and can 
also involve the upper extremities.14 
Of importance is the gamut of 
conditions that should be differentiated. 
Hexa carbon abuse, as in glue sniffing, can 
simulate Guillain-Barre syndrome. 
Diptheria presents similar findings in its 
later stages; therefore recent infection of 
diphtheria must be taken into 
consideration15. Others that should be 
considered are poliomyelitis, any evidence 
of porphyria, botulism, lead or arsenic 
intoxication, tick paralysis as in Lyme 
disease, and acute toxic neuropathies 
(from organ phosphorus compounds). It is 
therefore important to accurately and 
thoroughly evaluate any cause of acute 
weakness16.  
An objective index for diagnosis 
can be made utilizing motor evoked 
potentials (MEP). Cui found in 27 patients 
with GBS that the findings of MEP were 
consistent with pathological changes of 
demyelination and clinical distribution of 
muscle weakness. good correlation 
between abnormal MEP and degree of 
muscle weakness (p 0.01) was noted. He 
also found that MEP can be used for 
differential diagnosis as well as follow-up 
and effect of therapy17. MEP is painless 
and can be done easily and repeated. The 
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pathogenesis of Guillain-Barre syndrome 
shows edematous changes proximal to the 
spinal nerve root at the junction of the 
anterior and posterior roots. The myelin 
sheaths soon become irregular at about the 
third day. Lymphocytes appear about the 
ninth day and phagocytosis on the eleventh 
day. These findings were found in severe 
cases of this syndrome that led to death18.  
Researchers believe that the 
myelin destruction is limited to those areas 
of nerve trunks with intense inflammation 
suggesting that the inflammatory cells 
have direct effect initiating the 
demyelination. The demyelination occurs 
primarily in areas infiltrated with 
inflammatory cells. Degeneration of the 
basement membrane of the Schwann cell 
results complication19. This is due to 
macrophages in the presence of 
lymphocytes and not lymphocyte by 
themselves20.This breakdown, which is 
unclear, is associated with an autoimmune 
attack on component of peripheral 




Treatment for patients with 
Guillain-Barre syndrome depends on 
whether they have mildly acute, severely 
acute or chronic involvement. The 
incidence of death in one study was 1.5% 
to 8% of patients22. Another study listed 
the death rate at 4%23.Other common 
complications include ventilatory failure 
and cardiovascular instability for which 
intensive care support should be utilized. 
Ventilatory failure is caused by 
involvement of airway and respiratory 
muscles, particularly the diaphragm. 
Cardiovascular instability is due to 
involvement of the autonomic nervous 
system and results in labile blood pressure, 
cardiac arrhythmias, and hypovolemia. 
Compressive neuropathies occur in 
patients with protracted weakness and are 
an important cause of residual 
neurological deficits. The use of 
corticosteroids demonstrated no benefit23. 
The only well-investigated efficacious 
immune modulator therapy is 
plasmapheresis24. Plasma pheresis has 
been shown to decrease ventilator 
dependence in severe Guillain-Barre 
syndrome. No irreversible complications 
of plasmapheresis were observed. In all 
cases of this condition special emphasis 
should be given to psychological support 
and management of pain24.persistent 
residual paresis occurs in severe cases and 
high majority of these patients ultimately 
have good functional recovery and can 
recover completely at about 12 months 
after onset 23. 
 
CONCLUSION 
Guillain-Barre syndrome is 
neurological disorder resulting primarily 
in muscle paralysis that in most cases is 
symmetrical. Patients may have mild 
involvement or severe involvement which 
may in small percentage lead to death. 
Patients may present to chiropractic office 
with symptoms of polyradiculoneuralgia 
which may at first be interpreted as 
radicular pain pattern of spinal origin. It is 
extremely important to identify and 
urgently refer; potential severe cases in 
order to have the appropriate 
investigations (i.e. electrodiagnostic 
studies, spinal tap) instituted and have the 
appropriate care administered. Differential 
diagnosis is of utmost importance. 
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